IRVINE, Calif., Sept. 9, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announces the launch of Morpheus8 Cool, the next evolution of ...

Calls on Board to Form a Truly Independent Special Committee and Retain an Independent Investment Bank to Immediately Engage with Steel around Its Superior Offer NEW YORK--(BUSINESS WIRE)--Steel ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

InMode announced the appointment of Dr. Shlomo Nass as Chairman of the Board and Moshik Itzkovich as Chief Financial Officer, with both appointments effective immediately. Dr. Nass succeeds Dr.

InMode remains a 'Hold' as its cheap valuation is offset by margin decay, flat growth, and strategic uncertainty. INMD faces declining gross margins (from mid-80s percent to 75–77%) and slowing ...

Jan 28 (Reuters) - Investment firm Steel Partners said on Wednesday it had offered $18 per share to acquire a 51% stake in InMode (INMD.O), opens new tab, ‌sending the Israel-based medical technology ...

InMode is rumored to be in advanced deal talks with a foreign investment fund, Calcalist, an Israeli newspaper reported this week. According to the report, the medical aesthetic device company could ...

A foreign investment fund could scoop up medical aesthetics outlet InMode (INMD) for $1.1 billion, an analyst said Monday as InMode stock surged to a three-month high. Calcalist, an Israeli news ...

I'm downgrading InMode from a 'Strong Buy' to a 'Buy' due to consistent guidance cuts and short-term demand issues. Despite recent performance issues and high interest rates, INMD still holds a strong ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Medical devices company InMode (NASDAQ:INMD) has fallen out of favor with investors in the past two years for various reasons, which we'll explain below. However, now that it's down 76% from highs, ...